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Protein kinase Msk1 physically 
and functionally interacts with the KMT2A/MLL1 
methyltransferase complex and contributes 
to the regulation of multiple target genes
Maaike Wiersma1, Marianne Bussiere1,3, John A. Halsall1, Nil Turan1, Robert Slany4, Bryan M. Turner1 
and Karl P. Nightingale2*
Abstract 
Background: The KMT2A/MLL1 lysine methyltransferase complex is an epigenetic regulator of selected develop-
mental genes, in part through the SET domain-catalysed methylation of H3K4. It is essential for normal embryonic 
development and haematopoiesis and frequently mutated in cancer. The catalytic properties and targeting of KMT2A/
MLL1 depend on the proteins with which it complexes and the post-translational protein modifications which some 
of these proteins put in place, though detailed mechanisms remain unclear.
Results: KMT2A/MLL1 (both native and FLAG-tagged) and Msk1 (RPS6KA5) co-immunoprecipitated in various cell 
types. KMT2A/MLL1 and Msk1 knockdown demonstrated that the great majority of genes whose activity changed on 
KTM2A/MLL1 knockdown, responded comparably to Msk1 knockdown, as did levels of H3K4 methylation and H3S10 
phosphorylation at KTM2A target genes HoxA4, HoxA5. Knockdown experiments also showed that KMT2A/MLL1 is 
required for the genomic targeting of Msk1, but not vice versa.
Conclusion: The KMT2A/MLL1 complex is associated with, and functionally dependent upon, the kinase Msk1, 
part of the MAP kinase signalling pathway. We propose that Msk1-catalysed phosphorylation at H3 serines 10 and 
28, supports H3K4 methylation by the KMT2A/MLL1 complex both by making H3 a more attractive substrate for 
its SET domain, and improving target gene accessibility by prevention of HP1- and Polycomb-mediated chromatin 
condensation.
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Background
The human KMT2 proteins (formerly known as mixed-
lineage leukaemia, MLL proteins) are highly conserved, 
SET domain-containing lysine methyltransferases, 
homologous to the Drosophila trithorax group pro-
teins TRX (trithorax), TRR (TRX-related) and dSET1 
[1, 2]. Like their Drosophila homologues, they main-
tain and enhance the activity of genes with key roles in 
differentiation and development [2], in part by regulating 
levels of histone 3 lysine 4 (H3K4) methylation, thereby, 
directly or indirectly, modifying chromatin structure [3, 
4]. In humans, the KMT2 family comprises three pairs 
of paralogues, namely KMT2A and 2B (dTRX homo-
logues, originally MLL1 and 2), KMT2C and 2D (dTRR 
homologues, originally MLL3 and 4) and KMT2F and G 
(dSET1 homologues, originally hSET1A and hSET1B). 
KMT2 family members are frequently mutated in leu-
kaemias [5] and other cancers [6]. In  vivo, the KMT2 
enzymes are found in multi-subunit complexes of which 
three proteins, WDR5, RbBP5 and ASH2L, provide a 
common stoichiometric core (reviewed in [1, 7]). These 
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proteins enhance the weak catalytic activity of recombi-
nant KMT2 by 50–500-fold [8, 9]. DPY30 also frequently 
associates with the core complex, providing a further 
twofold increase in methyltransferase activity [9]. In 
addition to these common components, complexes built 
on each one of the three KMT2 subgroups can interact 
with a unique set of binding proteins. For example, only 
KMT2A/B complexes contain multiple endocrine neo-
plasia type 1 (MENIN) [10] and lens epithelium-derived 
growth factor (LEDGF) [11]. These proteins seem to 
mediate interaction with transcription factors such as 
oestrogen receptor [12] and therefore influence gene tar-
geting. In addition, KMT2 complexes have been shown 
to interact dynamically with a variety of transcription 
factors, including E2Fs [13] and p53 [14] amongst several 
others (see [1, 7] for further details). It is likely that these 
variable protein associations make a major contribution 
to the catalytic properties and gene regulation profiles of 
the three KMT2 subgroups.
All KMT2 subgroups are specific for H3K4, but 
catalyse different methylation states. Recombinant 
KMT2A/B complexes give mono- and di-methylation 
(H3K4me1, H3K4me2), with only weak trimethylation [1, 
15, 16]. KMT2C/D complexes give predominantly mono-
methylation, whilst KMT2F/G complexes are capable 
of mono-, di- and trimethylation [1]. The distinction is 
important, given that the different methylation states 
of H3K4 play different roles in transcriptional control. 
H3K4me1 is a consistent marker of regulatory enhancers 
[17, 18], whereas H3K4me3 is, amongst other things, a 
marker of active promoter regions [19, 20]. Various fac-
tors could contribute to these detailed, but functionally 
important, catalytic differences. For example, H2B ubiq-
uitination enhances the activity of KMT2A/MLL1 and 
KMT2F, but not KMT2C [16]. In addition, post-transla-
tional modification of individual subunits can influence 
catalytic properties; for example, SUMOylation of RbBP5 
inhibits KMT2A/MLL1 by disrupting its association with 
ASH2L [21]. These events may account for the occasional 
discrepancies between the catalytic properties of purified 
complexes and those reconstituted in vitro from recom-
binant proteins (see [1] for original references). Thus, 
much remains to be learned about the ways in which 
interacting factors and post-translational protein modi-
fications determine the characteristic properties of par-
ticular KMT2 complexes. As the catalytic and structural 
requirements for the KMT2 complex are likely to be con-
text dependent, varying from one cell type or develop-
mental stage to another, any individual cell may contain 
a dynamic and variable population of complexes with dif-
ferent protein components.
The results presented here focus on the most widely 
studied mammalian KMT2, namely the TRX homologue 
KMT2A/MLL1. Human KMT2A is a large protein, 3963 
amino acids which, uniquely within the KMT2 family, 
contains two sites that can be cleaved by the threonine 
aspartase Taspase 1 [22, 23]. (Its paralogue, KMT2B, 
contains only one such site.) Taspase 1 cleavage of newly 
translated KMT2A/MLL1 generates 320  kDa  N-termi-
nal and 180 kDa C-terminal fragments [24], which then 
form a non-covalent, heterodimeric complex. How this 
cleavage step contributes to KMT2A/MLL1 function 
remains uncertain [25], but it is likely that it allows the 
more effective configuration of the various functional 
domains spread across the protein. These include the 
lysine methyltransferase (SET) domain [3, 19]), and vari-
ous protein-binding (PHD, bromo-domains [26]) and 
DNA-binding (CXXC, AT hook) domains [27, 28]). After 
post-translational processing, KTM2A/MLL1 is incorpo-
rated into a functional, multi-protein complex containing 
the four core components common to all KMT2 com-
plexes (outlined above), plus a variable number of addi-
tional components [29]. Some of these confer specific 
catalytic properties, including the lysine acetyltransferase 
CBP/KAT3A, which is necessary for the complex to acti-
vate transcription [30, 31], and MOF/KAT8, which spe-
cifically acetylates lysine 16 on histone H4, a modification 
known to decondense chromatin [32].
The association of histone acetyltransferases with 
KMT2A complexes and the effect of H2B ubiquitination 
on its methyltransferase activity exemplify the complex 
interactions (‘cross-talk”) of histone post-translational 
modifications (PTMs) as determinants of chromatin 
function. We have shown previously that global his-
tone hyperacetylation induced by histone deacetylase 
inhibitors is accompanied, in at least some cell types, by 
increased methylation of H3K4 [33, 34]. In an attempt to 
explain this, we asked how PTMs might affect the abil-
ity of the H3 Tail to act as a methyltransferase substrate. 
In  vitro assays using a recombinant SET domain meth-
yltransferase and synthetic peptide substrates showed 
that H3 mono-, di- and trimethylation were maximally 
enhanced by acetylation of both H3K9 and H3K14, 
together with phosphorylation of H3S10 [33]. Here, 
we address the in  vivo significance of H3S10 phospho-
rylation for function of the KMT2A methyltransferase 
complex and examine the mechanism by which this 
modification is put in place. We show that mitogen- and 
stress-activated kinase, Msk1 (also known as RPS6KA5), 
is physically associated with the KMT2A/MLL1 com-
plex in  vivo and is necessary for the regulation of key 
KMT2A-regulated genes.
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Results
KMT2A and Msk1 are physically associated in various cell 
lines
The in vitro methylation of H3K4 by the KMT2A/MLL1 
SET domain is strongly enhanced by phosphorylation of 
the histone peptide substrate at serine 10 [33], raising the 
possibility that phosphorylation of this residue may influ-
ence the gene regulatory activity of the KMT2A/MLL1 
complex in vivo. Phosphorylation of H3S10 in chromatin 
can occur through the action of the closely related kinases 
Msk1 and Msk2 [35, 36], so we explored the possibility 
that Msk1 might operate as part of the KMT2A/MLL1 
complex. Msk1 is constantly expressed in the cells but is 
active only after (auto-) phosphorylation and allosteric 
changes induced by ERK1 or 2 [37]. The antibody used 
for these experiments is specific for Msk1 phosphoryl-
ated at S360, one of the last residues to become phospho-
rylated, and detects active Msk1 [38]. In three different 
cell types—human lymphoblastoid cells (LCLs), mouse 
embryo fibroblasts (MEFs) and human embryonic kidney 
cells (HEKs)—material precipitated with antibodies to 
KMT2A contained readily detectable amounts of Msk1 
(Fig.  1a). The protein often migrated as a double band, 
possibly due to allosteric changes and/or differences in 
phosphorylation status (Fig.  1a). Conversely, antibodies 
to Msk1 immunoprecipitated KMT2A/MLL1 (Fig.  1b, 
full-length blots from 1A and 1B are shown in Addi-
tional file  1). To validate this interaction, FLAG-tagged 
KMT2A/MLL1 was overexpressed in HEK293 cells and 
the associated complex purified (Fig.  1c). Western blot 
analysis of the immunoprecipitated complex confirmed 
that it contained the FLAG-tagged KMT2A/MLL1 and 
also Msk1, but not NFκB, a known interaction partner of 
Msk1 [39] readily detected in the lysate (Fig. 1c). It seems 
that the KMT2A/MLL1–Msk1 interaction is specific, 
stable and present in a range of mouse and human cell 
types.
KMT2A and Msk1 knockdowns trigger similar expression 
changes in KMT2A target genes
We analysed the possible functional impact of the 
KMT2A/MLL1–Msk1 interaction by using a knock-
down approach in MEFs. These cells express HoxA 
genes, known KMT2A/MLL1 targets [40]. Transient 
siRNA-mediated knockdown conditions were estab-
lished for KMT2A/MLL1, resulting in a >40% reduc-
tion in the protein (Fig.  2a) that was well tolerated by 
the cells. The knockdown was specific, with no impact 
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Fig. 1 Co-immunoprecipitation of KMT2A and Msk1. a Western blots analysing KMT2A-immunoprecipitated material from human lymphoblastoid 
cells (LCLs), mouse embryonic fibroblasts (MEFs) and human embryonic kidney cells (HEKs). The precipitated material tested positively for Msk1. 
A representative western (1 out of 3) is shown. b Western blots analysing Msk1-immunoprecipitated material from the indicated cell lines. The 
precipitated material tested positively for KMT2A. A representative western (1 out of 3) is shown. c FLAG-KMT2A was overexpressed in HEK293 cells, 
immunoprecipitated using FLAG antibodies and characterised by SDS gel (silver nitrate stain, left panel). The gel was Western-blotted and the filter-
stained sequentially with antibodies to FLAG, phosphorylated Msk1 and NFκB as indicated
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on the transcripts of other mouse KMT genes (Fig. 2b). 
For Msk1, we established well-tolerated knockdown con-
ditions that reduced Msk1 protein abundance by >90% 
(Fig. 2c), whilst leaving protein and transcript levels of its 
close paralogue Msk2 unaffected (Fig. 2c, d).
We used expression analysis on high-density microar-
rays to identify genes whose expression was sensitive to 
knockdown of KMT2A/MLL1 or Msk1. Using a fold change 
cut-off of 2 and false discovery rate <10%, 3912 different 
genes changed expression in response to either KMT2A/
MLL1 or Msk1 knockdown. Undirected cluster analysis 
(SOTA) separated the responding genes into five groups, as 
shown in Fig. 2e. The up- and down-regulation of selected 
genes was validated by RT-qPCR (Additional file 2).
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Fig. 2 Effects of KMT2A/MLL1 and Msk1 knockdown on HoxA gene expression. a Western analysis of KMT2A/MLL1 abundance in mouse embryo 
fibroblasts (MEFs), either mock-transfected (Con) or KMT2A/MLL1 knockdown (KD). RNA polymerase II (Pol II) was used as a loading control and to 
calculate the extent of KMT2A/MLL1 knockdown (37% of control). Full-length blots are given in Additional file 1. b RT-qPCR expression analysis of 
a selection of KMT2 genes in knockdown cells using actin as a control and with mock-transfected cells normalised to 1.0 (n = 3, T test, *p < 0.05; 
**p < 0.01; ***p < 0.001). The KMT2E protein has no methyltransferase activity (see text). c Western analysis of Msk1 and Msk2 in mock-transfected 
(Con) and Msk1 knockdown (KD) MEFs. Actin was used as a loading control and to calculate the extent of Msk1 knockdown (1% of control). A 
representative western (1 out of 3) is presented. Full-length blots are given in Additional file 1. d RT-qPCR expression analysis of Msk1 and 2 in Msk1 
knockdown cells. Transcripts were analysed using actin as a control, with the level of transcripts in mock-transfected cells normalised to 1.0 (n = 3, T 
test, *p < 0.05; **p < 0.01; ***p < 0.001). e Relative gene expression levels in control (n = 3), KMT2A/MLL1 knockdown (n = 4) and Msk1 knockdown 
(n = 3) cells are indicated by colour intensity from 2.7-fold down-regulated (green) to 2.7-fold up-regulated (red). 3912 genes showed significant 
changes in expression following KMT2A/MLL1 and/or MSK1 knockdown and these were clustered into five groups by SOTA analysis; the number of 
genes in each cluster is indicated. f Venn diagrams showing the numbers and relationship of genes down-regulated (upper panel) or up-regulated 
(lower panel), by knockdown of KMT2A/MLL1 and/or Msk1. The corresponding SOTA cluster is indicated in brackets
Page 5 of 12Wiersma et al. Epigenetics & Chromatin  (2016) 9:52 
Strikingly, all 758 genes that were significantly down-
regulated in response to the loss of KMT2A/MLL1 
[cluster 3 genes] were also down-regulated in response 
to the loss of Msk1 (Fig.  2f, upper panel). Thus, all 
genes whose ongoing transcriptional activity is depend-
ent on KMT2A/MLL1 (i.e. that are down-regulated by 
KMT2A KD) are also dependent on Msk1. The overlap 
of responding genes was much greater than expected 
by chance (Chi-squared test with Yates correction, two-
tailed p value <0.0001), indicating a functional relation-
ship between the two enzymes. This 100% overlap is not 
attributable to down-regulation of Msk1 in KMT2A/
MLL1 KD cells or vice versa. Expression of KMT2A/
MLL1 in Msk1 knockdown cells was not significantly 
altered, whereas the expression of Msk1 showed a mod-
est up-regulation in response to the loss of KMT2A/
MLL1 (Additional file 3).
Likewise, of the genes up-regulated in response to 
KMT2A/MLL1 KD, a majority (448, 62%) were also up-
regulated in response to Msk1 KD (Fig. 2f, lower panel). 
However, these overlapping, up-regulated genes repre-
sent only a minority (19%) of the 2331 genes up-regulated 
in total by Msk1 KD (i.e. genes whose ongoing activity 
is repressed by Msk1). It seems that Msk1 alone, acting 
either directly or indirectly through phosphorylation of 
regulators such as NFkB or CREB [39, 41], is frequently 
involved in transcriptional repression.
Ontology analysis of significant genes was consistent 
with KMT2A/MLL1 and Msk1 activating a wide range of 
gene targets (Additional file 4). Genes down-regulated by 
KMT2A/MLL1 and Msk1 KD were modestly (1.5–1.9-
fold), though significantly enriched in general terms such 
as glycoprotein and extracellular region activity. In con-
trast, genes down-regulated by KD of Msk1 alone were 
enriched selectively in cell cycle terms (130 out of 543 
genes), with high enrichments (3.5–9.8-fold). The gene 
set whose activity depends on Msk1 alone differs funda-
mentally from that requiring both Msk1 and KMT2A/
MLL1. These very different gene sets may account for 
the different degrees of knockdown tolerated by the cells, 
almost complete for Msk1 and ~40% for KMT2A/MLL1 
(Fig. 2c).
KMT2A/MLL1 brings Msk1 to HoxA target genes 
to regulate their expression
We examined the effects of KMT2A/MLL1 and Msk1 
knockdown on expression of genes within the HoxA clus-
ter, important and well-described KMT2A/MLL1 target 
genes. Knockdown of KMT2A/MLL1 resulted in signifi-
cant down-regulation of multiple HoxA genes, particu-
larly those nearer the centre of the cluster (Fig. 3a). Msk1 
knockdown generated a pattern of HoxA gene expression 
remarkably similar to that in KMT2A/MLL1 knockdown 
cells, with genes nearer the centre of the cluster, HoxA3–
6 and HoxA10, showing the greatest down-regulation 
(Fig. 3b).
In order to understand better the functional rela-
tionship between KMT2A/MLL1 and Msk1, we exam-
ined their interaction at the HoxA4 and HoxA5 loci, 
near the centre of the cluster and amongst the most 
severely down-regulated genes in both knockdowns. 
Using ChIP-PCR with antibodies to phosphorylated 
Msk1, using three primer pairs spanning the gene, we 
found that Msk1 is normally enriched over the HoxA4 
TSS (Fig.  3c, upper left panel). This enrichment is lost 
when KMT2A/MLL1 is knocked down (Fig.  3c, upper 
left panel), suggesting that Msk1 must interact with the 
MLL1 complex to be recruited to these sites. In con-
trast, whilst a peak of KMT2A/MLL1 was detected over 
the HoxA4 TSS, it did not change significantly upon 
Msk1 knockdown (Fig.  3c, upper right panel), indicat-
ing that Msk1 is not essential for the recruitment of the 
MLL1 complex. Exactly the same response to KMT2A/
MLL1 and Msk1 KD was detected across the HoxA5 
locus (Fig. 3c, lower panels). It is interesting to note that 
the peaks of KMT2A/MLL1 and Msk1 are located at the 
TSS of HoxA5, but upstream for HoxA4; so, their co-
location is not simple because they both are located at 
TSS (Fig. 3c).
To define how KMT2A/MLL1 and Msk1 interact to 
regulate H3 modification levels at MLL1 complex tar-
get loci, we characterised key histone modifications at 
HoxA4 and HoxA5 in the context of KMT2A/MLL1 
and Msk1 knockdown (Fig.  4a). Both H3K4me3 and 
H3K9acS10ph were enriched specifically at the TSS 
(left and middle panels). H3K4me3 fell to baseline lev-
els, both upon KMT2A/MLL1 knockdown as expected 
and also in Msk1 knockdown cells (Fig.  4a, left panels). 
Likewise, the TSS-associated mark H3K9acS10ph was 
reduced both in Msk1 knockdown cells as expected and 
in KMT2A/MLL1 knockdown cells (Fig. 4a, middle pan-
els). In contrast, the abundance of the silencing modifica-
tion H3K27me3, used as a control, did not change upon 
knockdown of either protein (Fig. 4a, right panels). These 
results show that the KMT2A/MLL1 complex is required 
for recruitment of Msk1 to the HoxA4 and HoxA5 loci, 
and consistent with the proposition that Msk1-catalysed 
H3S10 phosphorylation facilitates the KMT2A/MLL1 
complexes methyltransferase activity at these TSSs. 
However, the peaks of H3K4me3 and H3K9acS10ph at 
the HoxA4 TSS (Fig. 4a) do not coincide with the peaks 
of KMT2A and Msk1 at the same locus (Fig.  3c). Thus, 
whilst KMT2A and Msk1 are clearly necessary for the 
deposition of these histone modifications, the amount 
of enzyme at particular locations is not the sole determi-
nant of their levels.
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Discussion
The KMT2A/MLL1 is necessary for regulation of genes 
with key roles in differentiation and development [1, 2] 
[42–44]. It has multiple domains that mediate binding to 
both proteins and DNA, and allow assembly of the multi-
protein complex that regulates gene expression. KMT2A/
MLL1 has a SET domain that, within the complex, confers 
lysine methyltransferase activity specific for histone H3 
lysine 4 (H3K4), and is essential for gene regulation [3, 19]. 
The various proteins that form, or associate with, the core 
MLL1 complex regulate both its ability to methylate H3K4 
and its ability to locate and gain access to its target genes, 
but the mechanisms that underpin these processes are not 
yet understood [1, 7]. Here, we show that the kinase Msk1, 
part of the MAPK signalling pathway, physically interacts 
with the MLL1 complex, is essential for the regulation of 
KMT2A/MLL1 target genes and, at HoxA4 and HoxA5, 
that this is via regulation of H3K4 methylation.
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Fig. 3 HoxA gene expression and the distribution of KMT2A/MLL1 and Msk1 change upon KMT2A/MLL1 or Msk1 knockdown. a RT-qPCR expres-
sion analysis of HoxA genes in KMT2A knockdown cells, compared to mock-transfected control cells normalised to 1.0 (n = 3, T test, *p < 0.05; 
**p < 0.01; ***p < 0.001). b RT-qPCR expression analysis of changes in expression of HoxA genes in Msk1 knockdown cells (n = 3, T test, *p < 0.05; 
**p < 0.01; ***p < 0.001). c Effect of KMT2A/MLL1 knockdown on Msk1 binding (upper panels) or Msk1 knockdown on KMT2A binding (lower panels) 
across the HoxA4 gene (left hand panels) and HoxA5 gene (right hand panels). Binding was normalised to mock-transfected cells (n = 3, T test, 
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Four lines of evidence demonstrate the physical asso-
ciation of Msk1 with the KMT2A/MLL1 complex. First, 
KMT2A/MLL1 and Msk1 co-immunoprecipitate from 
extracts of several different cell types. Second, the two 
proteins co-localise across HoxA genes (known targets). 
Third, knockdown of Msk1 diminishes methylation of 
H3K4 at MLL1 complex target sites. Likewise, KMT2A/
MLL1 knockdown diminishes H3S10 phosphorylation 
at the same sites, suggesting that, in the absence of the 
KMT2A/MLL1 complex, Msk1 is not appropriately tar-
geted. This was confirmed by showing that KMT2A/
MLL1 knockdown prevented Msk1 recruitment to 
HoxA4 and HoxA5 genes, whilst Msk1 knockdown did 
not disrupt KMT2A/MLL1 binding. Finally, our finding 
that expression of 81% of KMT2A/MLL1-regulated genes 
are influenced by Msk1 knockdown, shows that the func-
tional interaction between Msk1 and the KMT2A/MLL1 
complex in  vivo is very frequent. Because our knock-
down experiments targeting Msk1 left its close homo-
logue Msk2 unaffected, we conclude that the effects we 
observe are mediated by Msk1 alone.
Msk1 is known to phosphorylate histone H3 at ser-
ines 10 and 28, as well as key regulatory proteins such as 
cAMP response element binding (CREB) [41] and NFκB 
[39]. All of these substrates can, potentially, alter gene 
expression. The choice of which substrate, or even which 
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potentially, improves access of the complex to condensed chromatin by reversing chromatin compaction
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lysine, to phosphorylate is likely to be context dependent 
[45, 46]. The catalytic properties of Msk1, previous data 
and the present results suggest that the enzyme regulates 
the KMT2A/MLL1 complex in one or both of two general 
ways, namely by enhancing SET domain-catalysed H3K4 
methylation and/or by allowing the complex to access 
condensed chromatin. We have shown previously that 
SET domain methyltransferase activity is enhanced by 
the acetylation and phosphorylation of the H3 substrate 
at lysines 9 and 14 and serine 10, respectively [33]. The 
most effective catalytic improvement was provided by the 
fully modified substrate (H3K9acS10phK14ac) [33]. We 
have now shown that recruitment of Msk1 to KMT2A/
MLL1 responsive genes and consequent increases in 
H3S10 phosphorylation leads to increased H3K4 methyl-
ation and up-regulation of transcription. In light of these 
data, we propose that (in addition to its other activities) 
Msk1-mediated phosphorylation of H3S10 directly stim-
ulates the ability of the KMT2A/MLL1 SET domain to 
methylate H3K4 in vivo. It may be that the recruitment 
of the lysine acetyltransferase CBP by the KMT2A/MLL1 
complex [31] also contributes to enhancement of H3K4 
methylation through enhanced acetylation of H3K9 and 
K14. This model is shown in Fig. 4b.
H3 serines 10 and 28 are both adjacent to lysine resi-
dues whose various modifications contribute to long- and 
short-term control of gene expression. H3K9 acetylation 
is associated with active gene promoters [47] whilst its 
methylation is associated with silent, condensed chroma-
tin (including centric heterochromatin) [48]. H3K9me-
mediated chromatin condensation is brought about 
largely through selective binding of heterochromatin 
protein 1 (HP1) [49, 50]. Msk1 phosphorylation of H3S10 
appears to act in this process as a ‘phospho-switch’ that 
can block HP1 binding to H3K9me3, and even displace 
pre-bound HP1 [51, 52], thereby preventing or reversing 
gene silencing. This has been characterised on the mouse 
mammary tumour virus (MMTV) promoter, where Msk1 
recruitment, along with the progesterone receptor (PR) 
and the extracellular signal-regulated kinase (Erk), leads 
to phosphorylation of H3S10 at the promoter, displace-
ment of HP1 and recruitment of RNA polymerase II and 
the activator protein Brg1 [53]. We propose that Msk1 
facilitates binding of the KMT2A/MLL1 complex to 
some target genes by H3S10 phosphorylation and conse-
quent diminution of HP1-mediated chromatin condensa-
tion (Fig. 4b).
Methylation of H3K27 is necessary for gene silencing 
by the Polycomb repression complex PRC2 [54] and is 
put in place, and bound, by a component of the complex, 
the methyltransferase Ezh2 [55]. Genes can be protected 
against PRC2-mediated silencing by H3K27 acetylation 
[56], and by modification of other H3 lysines [46, 57–
59], but phosphorylation of H3 at serine 28, catalysed 
by MSK1/2, is known to displace PRC2, presumably by 
disrupting binding to the adjacent, methylated residue 
[60, 61]. This is consistent with the increase in H3K28ph 
abundance observed at the promoter regions of genes 
that are transcriptionally activated when quiescent 3T3 
cells are stimulated back into growth [62]. H3S28 phos-
phorylation allows Polycomb-silenced genes to be reac-
tivated without the need to demethylate H3K27 and may 
play a role in allowing the KMT2A/MLL1 complex to 
access such genes.
In light of these results, the association of Msk1 with 
the MLL1 complex confers the potential ability to reverse 
both HP1-mediated and Polycomb-mediated chromatin 
silencing, as a prelude to selective gene activation. What-
ever the detailed mechanisms may prove to be, the close 
physical and functional association between the KMT2A/
MLL1 complex and Msk1 indicates novel routes by which 
the complex can implement its role as a transcriptional 
activator and developmental regulator.
Conclusion
The histone kinase Msk1 physically associates in  vivo 
with the KMT2A/MLL1 complex in human and mouse 
cells and is essential for the regulation of key develop-
mental target genes. This represents a direct functional 
link between the MAPK cell signalling pathway and 
KMT2A-/MLL1-mediated gene regulation. At least, part 
of this regulatory role is accomplished through histone 
modification, specifically methylation of H3K4 and phos-
phorylation of H3S10 and possibly H3S28.
Methods
Cell culture
Human lymphoblastoid cells (LCLs) with a normal kar-
yotype were generated by M. Rowe (Uni. Birmingham) 
and grown in RPMI 1640, 100  µg/ml streptomycin, 100 
U/ml penicillin and 10% FBS (Foetal bovine serum, Inv-
itrogen) at 37  °C, 5% CO2. Human embryonic kidney 
cells (HEKs) were cultured in DMEM, 100 µg/ml strep-
tomycin, 100 U/ml penicillin and 10% FBS at 37  °C, 5% 
CO2. Mouse embryonic fibroblasts (MEFs) were gener-
ated in-house, via isolation from Balb/c wild-type mouse 
embryos between day 12 and 15 of gestation, and cul-
tured in DMEM, 100  µg/ml streptomycin, 100 U/ml 
penicillin, 1/100 MEM non-essential amino acids, 1/1000 
2-mercaptoethanol and 10% FBS at 37 °C, 5% CO2. Only 
cells between passage 2 and 4 were used. Drosophila 
SL2 (Schneider line-2) cells were cultured in Schneider’s 
medium supplemented with 8% FBS and 1/100 penicil-
lin/streptomycin, and incubated at 26 °C.
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RNA extraction and RT‑qPCR
RNA was isolated using RNeasy Minikit (Quaigen), 
and reverse transcription/cDNA amplification per-
formed in one step using QuantiTech™ Sybr® Green 
Mix (Qiagen), according to the manufacturer’s instruc-
tions. Reactions used commercial primers (Qia-
gen: Msk1 QT00141554, actin QT01336772, HoxA1 
QT00248322, HoxA2 QT0062812, HoxA3 QT00138264, 
HoxA4 QT00174986, HoxA5 QT00098819, HoxA6 
QT00140742, HoxA7 QT00168707, HoxA9 QT00108885, 
HoxA10 QT00240212, HoxA11 QT00250404, HoxA13 
QT0027642, MLL1 QT00240954, MLL2 QT01075620, 
MLL3 QT00310527, MLL5 QT00279426), with three 
analyses performed for each sample. RT-qPCR was per-
formed on a 7900 HT machine (Applied Biosystems).
Isolation of proteins and detection
Cells were washed and incubated in lysis buffer [20 mM 
Tris–HCl pH 7.4, 100 mM EDTA, 10 mM NaCl, 1% Tri-
ton X-100, 1  mM β-glycerophosphate, 1  mM EGTA, 
5 mM sodium pyrophosphate, ‘Complete’ protease inhib-
itor (Roche)] for 30  min on ice. Insoluble material was 
removed by centrifugation and protein concentration 
determined by Coomassie Plus protein assay (Thermo 
Scientific). Proteins were separated by gel electropho-
resis and stained with silver nitrate or blotted for west-
ern analysis. Primary antibody binding was detected by 
fluorescently tagged secondary antibodies (Licor) and gel 
loading normalised using anti-actin or anti-Pol II anti-
bodies (Abcam).
Antibodies
Antibody for H3K4me3 (R612) was generated in-house 
[63, 64]. Other antibodies were obtained commercially: 
H3K9acS10p [Abcam ab12181]; H3K27me3 [Millipore 
07-449]; phosphorylated Msk1, this antibody is specific 
for Msk1 phosphorylated at S360, one of the last resi-
dues to become phosphorylated and detects active Msk1 
[Abcam ab81294]; KMT2A [Millipore 05-764]; Msk2 
[R&D systems MAB2310]; actin [Abcam ab1801]; RNA 
Pol II [Abcam ab5408]; NFκB [Abcam ab7970-1]; FLAG 
[Sigma F1804].
Chromatin immunoprecipitation (ChIP)
Immunoprecipitation of micrococcal nuclease-digested, 
native chromatin coupled to quantitative PCR (qPCR) 
was used to determine levels of histone modification at 
selected genomic regions, as previously described [65, 
66].
Immunoprecipitation of formaldehyde cross-linked 
chromatin (X-ChIP) in MEFs was carried out essentially 
as described [67, 68]. Briefly, MEFs were cross-linked 
with 1% para-formaldehyde in medium for 10 min at RT. 
The reaction was quenched by the addition of 200  mM 
glycine before washing the cells twice with ice-cold 
PBS. Cells were resuspended in lysis buffer [1% SDS, 
10 mM EDTA, 50 mM Tris–HCl, pH 8, complete inhibi-
tor cocktail(Roche)] to a concentration of 105 cells in 
500  μl and sonicated at high power with 30  s ON/OFF 
for 7 cycles (Bioruptor, Diagenode). The chromatin was 
diluted 1:2 with dilution buffer [1% Triton X-100, 2 mM 
EDTA, 20  mM Tris–HCl, pH 8, 150  mM NaCl, com-
plete inhibitor cocktail (Roche)]. Protein G Dynabeads 
(Thermo Fischer) were prepared resuspended in citrate–
phosphate buffer (0.1 M citric acid, 0.1 M Na2HPO4) with 
0.5% BSA. Beads were coated with antibodies for 2 h at 
4 °C. The beads were washed twice, added to the chroma-
tin solution and incubated for 4 h at 4 °C. The beads were 
washed twice with low-salt buffer (1% Triton X-100, 0.1% 
SDS, 2  mM EDTA, 150  mM NaCl, 20  mM Tris–HCl, 
pH 8) and twice with high-salt buffer (1% Triton X-100, 
0.1% SDS, 2  mM EDTA, 100  mM NaCl, 20  mM Tris–
HCl, pH 8). The bound material was eluted with Elution 
buffer (100  mM NaHCO3, 1% SDS decross-linked, and 
the DNA extracted with QIAquick PCR purification kit 
(QIAGEN). Primer pairs used for analysing ChIP DNA 
by qPCR are listed in Additional file 5.
Co‑immunoprecipitation
Co-immunoprecipitation experiments were carried out 
as described before, using 1  ×  108 cells per precipita-
tion and in the presence of 50 µg/ml ethidium bromide, 
in order to release chromatin bound proteins from DNA 
[69–72]. Cells were lysed in NP40 buffer [1% NP40, 10% 
glycerol, 50 mM Tris pH 7.5, 0.1% sodium azide, 150 mM 
NaCl, complete proteinase inhibitor (Roche)] for 20 min 
on ice before sonication (high power, 10  s, Bioruptor 
Diagenode). The lysate was cleared by centrifugation 
(10 min, 17000g, 4 °C) and pre-cleaned by adding protein 
A Sepharose beads for 30 min at 4 °C. The cleaned lysate 
was incubated overnight with 15 µg of antibody at 4  °C 
on a rotating wheel and then with 40 µl beads for 3 h at 
RT. The beads were washed three times  with high-salt 
buffer (1% NP40, 10% glycerol, 50 mM Tris pH 7.5, 0.1% 
sodium azide, 200 mM NaCl). The beads were analysed 
on a SDS gel and western analysis, together with a no-
antibody control and 10% input samples.
Overexpression of FLAG‑MLL1 and FLAG precipitation
HEK293 cells were split the day before transfection 
and 4 ×  106 cells seeded into 10  cm plates in complete 
medium. The next day, a mix of 15  μg vector DNA 
(pMSCV-FLAG-MLL1, R. Slany, University Erlangen), 
1000  μl OptiMEM (Gibco) and 60  μl of polyethyle-
neimine (1 mg/ml, Polyscience Inc.) per plate was incu-
bated for 15 min at RT prior to addition to the plates. The 
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cells were cultured at 37 °C, 5% CO2 for 3 days and har-
vested, washed with TBS and resuspended in lysis buffer 
(1× TBS, 1  mM EDTA, 1% TritonX-100). Cells were 
incubated on ice for 30 min prior to centrifuging (15 min, 
13,000 rpm, 4 °C), addition of 50 μl anti-FLAG M2 mag-
netic beads (Sigma) and incubation for 2  h at RT with 
rotation. Beads were washed with TBS and FLAG-MLL1 
was eluted using 5 μg of 3× FLAG peptide (Sigma) and 
diluted in 500  μl TBS. The beads were incubated twice 
with 250 μl elution for 30 min, 4 °C with rotation and the 
supernatants pooled.
shRNA knockdowns
shRNA vectors were purchased from Origene (Msk1: 
TR504795; MLL1: TR517798) and transfected into MEFs 
by electroporation (GenePulser XCell, Bio-Rad). MEFs 
were brought into a single cell suspension by trypsination 
and washed with ice-cold PBS. 4 × 106 cells per transfec-
tion were resuspended in 400  μl electroporation buffer 
(10 mM Hepes, pH 7.5, 135 mM KCl, 2 mM MgCl2, 5 mM 
EGTA, 25% FBS) and transferred to a 4 mm electropora-
tion cuvette (Bio-Rad). 20 μg of vector DNA was added to 
the cells immediately before transfection and incubated on 
ice for 1 min. Cells were transfected with one pulse (300 V, 
600 μF, 1000 Ω) and allowed to recover (RT, 1 min), before 
addition of 10 ml pre-warmed MEF medium and incuba-
tion at 37 °C, 5% CO2 for 6 h. Non-transfected cells were 
removed by puromycin treatment (10 μg/ml, 14 h). After 
20 h, cells were harvested. The KD efficiency is determined 
by quantitation of Wester blots using the corresponding 
loading controls for normalisation.
Gene expression arrays
Expression analysis was performed on MEFs trans-
fected with knockdown shRNA vectors, using Nimble-
Gen arrays (100718_MM9_EXP_HX12) containing 12 
individual 135  k arrays with 3 probes per sequence for 
42,576 sequences. 10  μg of RNA per array was isolated 
(RNeasy, Qiagen) and reverse transcribed using the 
cDNA synthesis system (NimbleGen). cDNA samples 
were labelled with the NimbleGen One-Colour DNA 
labelling kit and subsequently hybridised on the array, 
washed and scanned with the MS 200 Microarray Scan-
ner (NimbleGen). Four replicate transfections were car-
ried out for each knockdown and control but one control 
and one MSK1 KD replicate were eliminated as outliers. 
Data were extracted in DEVA (Nimblegen), processed 
with R (background correction and normalisation) and 
analysed with MeV (clustering, statistical analysis and 
visualisation). Statistical significance of co-regulated 
genes was analysed by 2 × 2 contingency tables and Chi-
squared analysis with Yates correction (GraphPad, www.
graphpad.com). Microarray data have been deposited in 
GEO (www.ncbi.nlm.nih.gov/geo), accession number 
GSE89141.
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